ovid therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. ovid’s drug candidate, ov101, is currently in development for the treatment of symptoms of angelman syndrome and fragile x syndrome. ovid is also developing ov935 in collaboration with takeda pharmaceutical company limited for the treatment of rare epileptic encephalopathies. ovid has initiated the phase 2 stars trial of ov101 in adults with angelman syndrome and a phase 1 trial in adolescents with angelman and fragile x syndrome to identify doses suitable for younger patients. review our community guidelines: http://www.ovidrx.com/community-guidelines/
Company profile
Ticker
OVID
Exchange
Website
CEO
Jeremy Levin
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
OVID stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
8 Mar 24
8-K
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
8 Mar 24
8-K
Other Events
6 Dec 23
EFFECT
Notice of effectiveness
16 Nov 23
424B5
Prospectus supplement for primary offering
15 Nov 23
CORRESP
Correspondence with SEC
13 Nov 23
UPLOAD
Letter from SEC
8 Nov 23
S-3
Shelf registration
3 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
3 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 59.37 mm | 59.37 mm | 59.37 mm | 59.37 mm | 59.37 mm | 59.37 mm |
Cash burn (monthly) | 4.73 mm | 68.34 k | 4.01 mm | 4.44 mm | 3.35 mm | 3.59 mm |
Cash used (since last report) | 28.15 mm | 406.84 k | 23.87 mm | 26.43 mm | 19.95 mm | 21.35 mm |
Cash remaining | 31.22 mm | 58.96 mm | 35.50 mm | 32.94 mm | 39.42 mm | 38.01 mm |
Runway (months of cash) | 6.6 | 862.8 | 8.9 | 7.4 | 11.8 | 10.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 129 |
Opened positions | 13 |
Closed positions | 23 |
Increased positions | 55 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 945.37 bn |
Total shares | 97.30 mm |
Total puts | 36.10 k |
Total calls | 16.90 k |
Total put/call ratio | 2.1 |
Largest owners | Shares | Value |
---|---|---|
AI Day 1 | 11.45 mm | $148.67 mm |
Ra Capital Management | 7.81 mm | $95.83 bn |
Atlas Venture Life Science Advisors | 7.61 mm | $93.35 bn |
FMR | 6.03 mm | $73.94 bn |
Atlas Venture Fund XI | 6.01 mm | $0.00 |
BLK Blackrock | 4.69 mm | $57.53 bn |
Vanguard | 4.63 mm | $56.81 bn |
BEN Franklin Resources | 4.07 mm | $49.91 bn |
Braidwell | 3.72 mm | $45.59 bn |
STT State Street | 2.94 mm | $36.02 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Mar 24 | Jeremy M Levin | Common Stock | Buy | Acquire P | No | No | 2.76 | 18,248 | 50.36 k | 3,616,715 |
22 Feb 24 | Tardio Jason | Common Stock | Grant | Acquire A | No | No | 0 | 28,125 | 0.00 | 28,125 |
22 Feb 24 | Tardio Jason | Stock Option Common Stock | Grant | Acquire A | No | No | 3.68 | 168,750 | 621.00 k | 168,750 |
22 Feb 24 | Jeffrey A Rona | Common Stock | Grant | Acquire A | No | No | 0 | 28,125 | 0.00 | 28,125 |
22 Feb 24 | Jeffrey A Rona | Stock Option Common Stock | Grant | Acquire A | No | No | 3.68 | 168,750 | 621.00 k | 0 |
22 Feb 24 | Robert Michael Poole | Stock Option Common Stock | Grant | Acquire A | No | No | 3.68 | 30,000 | 110.40 k | 30,000 |
22 Feb 24 | Thomas Michael Perone | Common Stock | Grant | Acquire A | No | No | 0 | 28,125 | 0.00 | 28,125 |
22 Feb 24 | Thomas Michael Perone | Stock Option Common Stock | Grant | Acquire A | No | No | 3.68 | 168,750 | 621.00 k | 168,750 |
News
Recap: Ovid Therapeutics Q4 Earnings
8 Mar 24
Ovid Therapeutics Q4 2023 GAAP EPS $(0.220) Misses $(0.100) Estimate, Sales $141.562K Beat $56.500K Estimate
8 Mar 24
Ovid Therapeutics Filed U.S. Patent Application #20240009160: Use Of (S)-3-amino-4-(Difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid In The Treatment Of Cancer
11 Jan 24